A new preclinical study led by researchers at Johns Hopkins University School of Medicine, along with teams from Drexel and Emory universities, finds that cannabidiol (CBD) may hold surprising antiviral and immunological benefits in the context of HIV.
The research, published by bioRxiv and indexed by the U.S. National Library of Medicine, used rhesus macaques as well as human immune cells derived from stem cells. The results showed that CBD, even without antiretroviral therapy (ART), suppressed viral replication and limited the establishment of viral reservoirs during acute SIV infection in monkeys. The effect was described as being comparable to that of standard first-line therapies.
Beyond viral suppression, CBD slowed CD4+ T cell decline, curbed the expansion of pro-inflammatory monocytes, and reduced interferon-driven cytokine release. These effects were also observed in human macrophages, T cells, and microglia treated with CBD in vitro. Importantly, the researchers noted that CBD only inhibited cytokines in the presence of HIV, suggesting it does not act as a broad immunosuppressant.
Mechanistically, CBD appeared to regulate endocannabinoid receptors and related modulators while inhibiting NF-κB and STAT1 activation—key pathways involved in inflammation and viral persistence. The authors conclude that these findings justify clinical trials to evaluate CBD as an adjunctive therapy alongside ART in people living with HIV.
